National Health (April 2026 Price Reductions) (Exercise of Ministerial discretion) Determination (No.1) 2026

Overview

The National Health (April 2026 Price Reductions) (Exercise of Ministerial discretion) Determination (No.1) 2026 was enacted to address the need for adjustments in the pricing of specific pharmaceutical items under the National Health Act 1953. This instrument was created to exercise the discretion of the Minister for Health and Ageing in determining the pricing of certain pharmaceutical brands, ensuring that the pricing aligns with policy objectives aimed at balancing affordability with the sustainability of the healthcare system. The determination identifies certain pharmaceutical items that will not undergo the otherwise applicable price reduction and others that will experience a reduced percentage of price reduction, providing a structured approach to managing pharmaceutical costs while considering therapeutic needs. This determination was made under the authority granted by subsection 99ACF(3) of the National Health Act 1953 and was issued by Rebecca Richardson, Assistant Secretary of the PBS Listing, Pricing and Policy Branch in the Technology Assessment and Access Division of the Department of Health, Disability and Ageing. The policy objective behind this determination is to ensure that the pricing of essential pharmaceutical items is managed in a way that supports access to necessary treatments while also reflecting broader economic and budgetary considerations within the health sector.

Scope and Application

The National Health (April 2026 Price Reductions) (Exercise of Ministerial discretion) Determination (No.1) 2026 is an instrument that applies to specific brands of pharmaceutical items as listed in Schedules 1 and 2. It aims to regulate the approved ex-manufacturer prices of these items, determining whether they will not be subject to price reductions or will instead undergo a lower percentage reduction than would otherwise apply, effective from 1 April 2026. This determination is made under the authority of subsection 99ACF(3) of the National Health Act 1953. The Act's provisions govern the pricing and listing of pharmaceutical items on the Pharmaceutical Benefits Scheme (PBS). The scope of this determination is limited to the pharmaceutical items specified in the schedules, and it does not extend to other types of pharmaceutical products not listed. The application of this determination is nationwide, aligning with the overarching jurisdiction of the National Health Act 1953. Any exclusions or exemptions are inherently defined by the items not listed in the schedules or by any future amendments or subordinate instruments that may further refine the application of this determination.

Key Provisions

The National Health (April 2026 Price Reductions) (Exercise of Ministerial discretion) Determination (No.1) 2026 (sections 1 to 6) establishes specific price reductions for certain pharmaceutical items as of 1 April 2026. Under section 5, certain pharmaceutical brands listed in Schedule 1 will have their approved ex-manufacturer prices and claimed prices (if applicable) not reduced, whereas those in Schedule 2 will experience a reduced price as specified in the relevant column of the schedule. The determination is made under the authority of subsection 99ACF(3) of the National Health Act 1953, which grants the Minister for Health and Ageing the discretion to adjust prices. The obligations imposed by the Act on the parties involved include compliance with the specified price reductions for the listed pharmaceutical items. Manufacturers and suppliers must adjust their pricing in accordance with the determination, ensuring that the approved ex-manufacturer prices and claimed prices reflect the mandated reductions. Additionally, the determination requires entities to maintain accurate records and documentation supporting the adjustments made to comply with the price reductions stipulated in the Act. Failure to comply with the provisions of this determination may result in civil and criminal consequences. While the specific penalties are not detailed in the text, under Australian law, breaches of similar determinations can lead to fines and, in severe cases, imprisonment. The exact penalties would depend on the nature and severity of the breach, as well as the specific provisions of the relevant Act. It is important for parties governed by this determination to adhere strictly to the requirements to avoid potential legal repercussions.